Skip to main content
. 2007 Aug;3(4):467–479. doi: 10.2147/vhrm.s1023

Figure 2.

Figure 2

Dose-related effect of Niaspan® (500–3000 mg/day) on lipid parameters in a 25-week, double-blind, randomized trial in 131 patients with hyperlipidemia. *p < 0.05 vs placebo. Effects of placebo have been omitted for clarity. Drawn from data presented by Goldberg et al (2000).